Eric Richman

Eric I. Richman has served as Chief Executive Officer of multiple biopharma and life science companies, including Tyrogenex, LabConnect, and PharmAthene, with leadership experience spanning early-stage biotech through late-stage clinical development and commercialization. He was a member of the founding team at MedImmune, where he played a key role in building the company from inception through its transformation into a leading biopharmaceutical enterprise and ultimate acquisition by AstraZeneca. He began his career in life science venture capital at HealthCare Ventures and has since held senior roles as a Venture Partner at Brace Pharma Capital and Allele Capital, as well as Advisor to Broad Oak Capital, a life science private equity firm. In addition, Eric serves as a business development advisor to major global biopharma and life science organizations including Novartis, Thermo Fisher Scientific, and Sanofi. Eric is an experienced biotech executive with a unique blend of expertise across biopharma, medical technology, clinical services, and life science investment, with a proven record in building companies, advancing novel therapeutics, and scaling operational infrastructures. He has guided organizations through strategic transformations, financings, partnerships, IPOs, and M&A transactions, while fostering high-performance teams and purpose-driven cultures